Janney Montgomery Scott Boosts Flexion Therapeutics, Inc. (FLXN) Price Target to $570.00

Share

Equity analyst Northland Securities added FLXN to its research portfolio by announcing an initial rating of "Outperform". (FOX) holds the market capitalization of $- along with - outstanding shares. The Flexion Therapeutics, Inc. has Relative Strength Index (RSI 14) of 73.34 along with Average True Range (ATR 14) of 1.65. Earnings surprises can have a huge impact on a company's stock price.

Analysts have given a mean recommendation of 2.80 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). It indicates oversold and overbought price levels for a stock.

Deutsche Bank & Trust Ag has 0% invested in Flexion Therapeutics Inc (NASDAQ:FLXN) for 44,163 shares. "(FLXN) Price Target to $570.00" was posted by Week Herald and is the property of of Week Herald. Raymond James And has invested 0.01% in Flexion Therapeutics Inc (NASDAQ:FLXN). To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road. Flexion Therapeutics has a one year low of $10.60 and a one year high of $29.41. The share last price represents uptick move of 1.77% in value from company's 52-Week high price and shows 87.88% above change in value from its 52-Week low price. The stock's market cap is $900.68 million.

Corker spat complicates drive for tax reform in Senate
These senators do, contra Bannon, have Trump's back, specifically so that they can get that bill signed into law. A typical sentiment, from Marco Rubio: "You'll have to ask Sen".

Currently Flexion Therapeutics (NASDAQ:FLXN)'s shares owned by insiders are 0.3%, whereas shares owned by institutional owners are 0%. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.11). Equities research analysts predict that Flexion Therapeutics will post ($3.75) EPS for the current year. However the six-month change in the insider ownership was recorded 5.67%, as well as three-month change in the institutional ownership was recorded -0.03%. The stock was acquired at an average cost of $24.15 per share, with a total value of $72,450.00.

Investors sentiment increased to 1.74 in 2017 Q2. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. The disclosure for this sale can be found here. They expect this year's earnings to fall -7.21% year-over-year to -$1.03, followed by -39.81% decline in the next year to -$0.62.

Looking at a public company's insider trading can give great insight into how the stock is performing. Guggenheim Capital LLC acquired a new stake in Flexion Therapeutics during the fourth quarter worth $1,326,000. Schwab Charles Investment Management Inc. now owns 101,214 shares of the specialty pharmaceutical company's stock valued at $2,047,000 after purchasing an additional 513 shares during the last quarter. Advisor Group Inc. grew its position in shares of Flexion Therapeutics by 205.9% during the second quarter.

OnScene: Updates from the US' World Cup qualifier vs. Trinidad and Tobago
The Seattle Sounders midfielder came off the bench in T&T's 3-1 loss to Mexico on Friday and will likely get the start on Tuesday. The island nation actually took the lead in the 66th minute, when Shahdon Winchester scored to give the Soca Warriors a 1-0 lead.

ILLEGAL ACTIVITY NOTICE: "Laidlaw Reiterates "Buy" Rating for Flexion Therapeutics, Inc". ProShare Advisors LLC now owns 18,750 shares of the specialty pharmaceutical company's stock valued at $379,000 after purchasing an additional 982 shares during the last quarter.

11/26/2014 - Flexion Therapeutics Inc had its "hold" rating reiterated by analysts at Summer Street.

Flexion Therapeutics, Inc., launched on November 5, 2007, is a specialty pharmaceutical company. The Firm is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The Business's lead product candidate, Zilretta (also known as FX006), is a late-stage, injectable, sustained-release, intra-articular (IA) steroid for patients with moderate to severe OA pain.

Ronaldo, Messi top Ballon d'Or list
He clinched last year's title ahead of Lionel Messi and Antoine Griezmann and is expected to be among the names announced later in the day.

Share